Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-11-21
1997-10-21
Datlow, Philip I.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514183, 514211, 540456, 540460, 540461, 540468, 540472, 540477, 540500, 540502, 540503, 540552, 540556, A61K 3155, C07D47108, C07D48708
Patent
active
056796730
ABSTRACT:
Certain aralkyl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R, R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower-alkyl, benzyl, and haloloweralkyl; wherein each of R.sup.2, R.sup.3 and R.sup.10 through R.sup.13 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein each of R.sup.8 and R.sup.9 is selected from hydrido, loweralkyl, benzyl and haloloweralkyl; wherein m is an integer of from two to four; wherein A is selected from phenyl, naphthyl, benzothiophenyl, benzofuranyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4204003 (1980-05-01), Szmuszkovicz
patent: 4463013 (1984-07-01), Collins et al.
patent: 4801604 (1989-01-01), Von Voightlander
patent: 4826839 (1989-05-01), King et al.
H!-(+)-pentazocine, a highly potent and selective radioligand for .sigma. receptors", FEBS Letters 251(1,2): 53-58 (Jul. 1989).
Rodd's Chemistry of Carbon Compounds, 2nd ed., Coffey, ED., vol. IV, Part H, Chapter 37, pp. 259, 278-284-Elsevier Scientific Publishing Company (1978).
Rothman, et al., Annals of Neurology, 19(2): 105-11 (1986).
Carter, et al., J. Pharm. Exp. Ther., 247(3): 1222-1232 (1988).
Gilman, et al., The Pharmacological Basis of Therapeutics, 7.sup.th ed., p. 404 Macmillan (1985).
Parsons, et al., Neuropharm, 25(2): 217-220 (1986).
Lason, et al., Brain Res., 482: 333-339 (1989).
DeCosta, et al., J. Med. Chem., 32(8): 1996-2002 (1989).
Long, et al., Soc. Neurosci. Abst., 16: 1122, Abst. 461.4 (1990).
Contreras, et al., Brain Res., 546: 79-82 (1991).
Scopes, et al., J. Med. Chem., 35:490-501 (1992).
DeCosta, et al., J. Med. Chem., 35(1): 38-47 (1992).
Radesca, et al., J. Med. Chem., 34(10): 3058-65 (1991).
Cheesman, et al., Derwent Abstract WO/92128 (1992).
Giardina, Biosistemi Come Targets Farmacologici, Recettori Peptidergici, Analgesisi Oppiodi Kappa: Sintesi E Relazioni Struttura-Attivita 'Di Piperidine Sostituite, pp. 21-63 (1992).
Rees, Biosistemi Come Targets Farmacologici, Recettori Peptidergici, Synthesis & Biological Activity of Kappa-Opioid Agonists Leading to the Selection of CI-9777 (Enadoline) for Clinical Investigation, pp. 65-101 (1992).
Ronsisvalle, Biosistemi Come Targets Farmacologici, Recettori Peptidergici, Requisiti Strutturali Per I Liganti Oppioidi: E'Possible Modulare La Selecttivita, pp. 102-133 (1992).
Aram et al., J. Pharmacol. Exp. Ther., 248, 320-328 (1989) Abstract only.
Bailey et al., Eur. J. Pharmacol., 240, 243-250 (1993).
Canoll et al., J. Neurosci. Res., 24, 311-328 (1989) Abstract only.
Clissold et al., J. Pharmacol. Exp. Ther., 265, 876-886 (1993).
Cook et al., J. Pharmacol. Exp. Ther., 263, 1159-1166 (1992) Abstract only.
DeCoster et al., Brain Res., 671, 45-53, (1995) Abstract only.
DeHaven-Hudkins et al., Life Sci., 56, 1571-1576 (1995) Abstract only.
Gewirtz et al., Neuropsychopharmacology, 10, 37-40 (1994).
Itzhak et al., FASEB J., 3, 1868-1872 (1989).
Kirk et al., J. Pharmacol. Exp. Ther., 271, 1080-1085 (1994) Abstract only.
Klein et al., J. Pharmacol. Exp. Ther., 260, 990-999 (1992) Abstract only.
Klein et al., Eur. J. Pharmacol., 254, 239-248 (1994).
Lasage et al., Synapse, 20, 156-64 (1995) Abstract only.
Loscher et al., Eur. J. Pharmacol., 238, 191-200 (1993).
Lysko et al., Stroke, 23, 414-419 (1992) Abstract only.
Lysko et al., Stroke, 23, 1319-1323 (1992) Abstract only.
Pontecorvo et al., Brain Res. Bull., 26, 461-465 (1991) Abstract only.
Reddy et al., J. Med. Chem., 37, 260-267, (1994) Abstract only.
Roth et al., Eur. J. Pharmacol., 236, 327-331 (1993).
Takahashi et al., Stroke, 26, 1676-1682 (1995) Abstract only.
Tam in Sigma Receptors, Y. Itzhak ed., Academic Press, Harcourt Brace & Co. Publishers, London (1994) ISBN 0-12-376350-9.
Tortella et al., Trends Pharmacol. Sci., 10:501-507 (1990).
Tortella et al., Trends Pharmacol. Sci.,11:146-147 (1990).
Weissman et al., Biol. Psych., 29, 41-54 (1991).
Witkin et al., J. Pharmacol. Exp. Ther., 266, 473-482 (1993).
Rennie, "The Mice That Missed", Scientific American, Jul. 1992, pp. 20, 26.
Schnabel, Science vol. 260, Jun. 18, 1993, pp. 1719-1720.
Bowen Wayne
de Costa Brian R.
Dominguez Celia
He Xiao-Shu
Rice Kenner C.
Datlow Philip I.
The United States of America, represented by the Department of H
LandOfFree
Aralkyl bridged diazabicycloalkane derivatives for CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aralkyl bridged diazabicycloalkane derivatives for CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aralkyl bridged diazabicycloalkane derivatives for CNS disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1006924